Hospital
Aurelia Osborn Fox Memorial Hospital Society
Aurelia Osborn Fox Memorial Hospital Society was paid $21.85M by Medicaid between Jul 2019 and Dec 2024, across 294 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoAURELIA OSBORN FOX MEMORIAL HOSPITAL SOCIETY
ONEONTA, NY 13820
ONEONTA, NY 13820
33aNPI1578529954assigned 04/25/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$21.85M
24GClaims403,965
24DCodes billed294
24AFirst – last monthJul 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#59 of 231
Median peer was paid$561K
This provider vs. median39×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 18,909 | $860K | |
| 2020 | 62,893 | $2.84M | |
| 2021 | 76,865 | $3.65M | |
| 2022 | 88,756 | $6.79M | |
| 2023 | 86,501 | $4.65M | |
| 2024incomplete | 70,041 | $3.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 18,980 | 17,889 | $3.67M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 19,190 | 16,897 | $2.64M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.8% | 13,296 | 12,654 | $1.71M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.1% | 8,658 | 8,288 | $1.55M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.6% | 6,755 | 6,449 | $1.22M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 4,163 | 4,048 | $821K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.7% | 2,718 | 2,502 | $589K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 2,496 | 2,459 | $580K |
| 80053 | Comprehensive metabolic panel | 2.2% | 16,320 | 15,292 | $471K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 7,892 | 2,830 | $436K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.0% | 9,232 | 8,850 | $426K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 1,615 | 1,597 | $424K |
282 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.9% | 3,622 | $411K |
| 81025 | 1.7% | 6,545 | $379K | |
| 99215 | Doctor's office visit, returning patient (complex) | 1.7% | 2,774 | $362K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.4% | 2,204 | $317K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 1,120 | $277K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.2% | 1,956 | $261K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.2% | 1,743 | $254K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 3,128 | $241K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.1% | 1,799 | $232K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 894 | $227K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,456 | $190K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,279 | $173K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,853 | $161K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,034 | $161K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,565 | $131K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,076 | $124K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,634 | $114K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,148 | $110K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 677 | $110K |
| 97161 | <1% | 1,329 | $108K | |
| 90686 | <1% | 4,128 | $107K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,911 | $104K |
| D0120 | Dental checkup, returning patient | <1% | 2,418 | $92K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,081 | $92K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 351 | $90K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,482 | $84K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 704 | $83K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,978 | $78K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,941 | $77K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,226 | $64K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 805 | $62K |
| 80051 | <1% | 1,397 | $55K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,559 | $55K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 356 | $55K |
| 80061 | Lipid panel | <1% | 5,440 | $52K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,113 | $52K |
| 86850 | <1% | 1,216 | $50K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,447 | $45K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 999 | $45K |
| D1110 | Prophylaxis - adult | <1% | 752 | $44K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 181 | $44K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 885 | $43K |
| 76830 | Ultrasound, transvaginal | <1% | 1,123 | $40K |
| D9997 | <1% | 842 | $40K | |
| 90715 | <1% | 1,599 | $39K | |
| 90651 | <1% | 505 | $38K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 154 | $38K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 687 | $38K |
| 12001 | <1% | 95 | $35K | |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 223 | $34K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,040 | $33K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 873 | $30K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,444 | $30K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,760 | $30K |
| 90670 | <1% | 1,229 | $29K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,045 | $26K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 15 | $25K |
| 87634 | <1% | 883 | $25K | |
| 86900 | <1% | 1,390 | $25K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,964 | $24K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 694 | $23K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 647 | $23K |
| 83880 | <1% | 898 | $23K | |
| 90677 | <1% | 408 | $21K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,150 | $20K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 77 | $20K |
| G0008 | Administration of influenza virus vaccine | <1% | 1,038 | $19K |
| 82607 | <1% | 1,801 | $19K | |
| 91322 | <1% | 241 | $18K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,419 | $18K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,316 | $18K |
| 90680 | <1% | 933 | $18K | |
| 90648 | <1% | 918 | $18K | |
| 86901 | <1% | 1,266 | $17K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 405 | $15K |
| 71271 | <1% | 230 | $14K | |
| 90633 | <1% | 645 | $14K | |
| 83655 | <1% | 1,142 | $14K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 364 | $13K |
| 92552 | <1% | 139 | $13K | |
| 71250 | <1% | 137 | $13K | |
| 96160 | <1% | 285 | $12K | |
| 90723 | <1% | 688 | $12K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 155 | $12K |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 108 | $12K |
| 90732 | <1% | 162 | $12K | |
| 84439 | <1% | 1,799 | $11K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,289 | $11K |
| D9310 | <1% | 158 | $11K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,736 | $11K |
| 84403 | <1% | 681 | $10K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,827 | $10K |
| 92551 | <1% | 183 | $9K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 235 | $9K |
| 82728 | <1% | 1,014 | $9K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 420 | $9K |
| 90700 | <1% | 410 | $9K | |
| 73564 | <1% | 1,020 | $9K | |
| D1206 | Topical application of fluoride varnish | <1% | 294 | $8K |
| 86618 | <1% | 1,020 | $8K | |
| 29125 | <1% | 28 | $8K | |
| 85610 | <1% | 2,312 | $8K | |
| 87481 | <1% | 232 | $8K | |
| 85027 | <1% | 3,191 | $8K | |
| 76801 | <1% | 161 | $8K | |
| 82565 | <1% | 1,822 | $7K | |
| 59025 | Fetal non-stress test | <1% | 41 | $7K |
| 90734 | <1% | 319 | $7K | |
| D1120 | Dental cleaning, child | <1% | 157 | $7K |
| 90656 | <1% | 348 | $7K | |
| 83735 | <1% | 5,048 | $7K | |
| 90697 | <1% | 298 | $7K | |
| 99406 | <1% | 329 | $7K | |
| 86803 | <1% | 1,134 | $7K | |
| 0001A | <1% | 188 | $7K | |
| 76770 | <1% | 84 | $6K | |
| 84702 | <1% | 1,368 | $6K | |
| 86780 | <1% | 900 | $6K | |
| 73610 | <1% | 1,009 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 404 | $5K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 37 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,964 | $5K |
| 84466 | <1% | 630 | $5K | |
| 76536 | <1% | 230 | $5K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,196 | $5K |
| 90480 | <1% | 248 | $5K | |
| 81513 | <1% | 228 | $5K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 129 | $4K |
| 12002 | <1% | 13 | $4K | |
| 0002A | <1% | 124 | $4K | |
| 0124A | <1% | 111 | $4K | |
| 0004A | <1% | 135 | $4K | |
| 73630 | <1% | 937 | $4K | |
| 94010 | <1% | 79 | $4K | |
| 73130 | <1% | 649 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 177 | $4K |
| 82948 | <1% | 1,293 | $4K | |
| 99442 | <1% | 33 | $4K | |
| 93017 | <1% | 32 | $4K | |
| 99443 | <1% | 31 | $3K | |
| 80076 | <1% | 259 | $3K | |
| 0071A | <1% | 100 | $3K | |
| 83540 | <1% | 908 | $3K | |
| 86666 | <1% | 613 | $3K | |
| 81003 | <1% | 5,327 | $3K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 33 | $3K |
| 95806 | <1% | 46 | $3K | |
| 0072A | <1% | 85 | $3K | |
| 0064A | <1% | 90 | $3K | |
| 87476 | <1% | 154 | $3K | |
| G0378 | Hospital observation service, per hour | <1% | 38 | $3K |
| 73030 | <1% | 475 | $3K | |
| 81001 | <1% | 5,570 | $3K | |
| 94060 | <1% | 12 | $3K | |
| 82670 | <1% | 193 | $3K | |
| 87070 | <1% | 1,226 | $2K | |
| 84153 | <1% | 176 | $2K | |
| 86140 | <1% | 1,218 | $2K | |
| 83690 | <1% | 5,119 | $2K | |
| 87653 | <1% | 37 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 15 | $2K |
| 94726 | <1% | 12 | $2K | |
| 87468 | <1% | 71 | $2K | |
| D0330 | Panoramic radiographic image | <1% | 55 | $2K |
| 0134A | <1% | 60 | $2K | |
| 82570 | <1% | 554 | $2K | |
| 93971 | <1% | 49 | $2K | |
| 0011A | <1% | 72 | $2K | |
| 84484 | <1% | 4,236 | $2K | |
| 97113 | <1% | 60 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 48 | $2K |
| 87077 | <1% | 1,133 | $2K | |
| 72110 | <1% | 125 | $2K | |
| 90710 | <1% | 90 | $2K | |
| 84520 | <1% | 1,567 | $2K | |
| 73110 | <1% | 388 | $2K | |
| 84450 | <1% | 1,783 | $2K | |
| 0012A | <1% | 53 | $2K | |
| D1351 | Sealant - per tooth | <1% | 37 | $2K |
| 85652 | <1% | 1,170 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 30 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,131 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,694 | $1K |
| 86762 | <1% | 246 | $1K | |
| 82550 | <1% | 1,718 | $1K | |
| 87186 | <1% | 891 | $1K | |
| 87484 | <1% | 71 | $1K | |
| 87478 | <1% | 71 | $1K | |
| 87469 | <1% | 71 | $1K | |
| 80306 | <1% | 1,955 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 554 | $1K |
| 87081 | <1% | 1,510 | $1K | |
| 84480 | <1% | 249 | $1K | |
| 82947 | <1% | 1,207 | $1K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 57 | $1K |
| 76642 | <1% | 52 | $1K | |
| 82043 | <1% | 273 | $982.02 | |
| 58300 | <1% | 14 | $980.86 | |
| 85379 | <1% | 1,196 | $917.99 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 60 | $861.35 |
| 87340 | <1% | 271 | $846.13 | |
| 70486 | <1% | 12 | $802.01 | |
| 90707 | <1% | 26 | $797.18 | |
| 85730 | <1% | 1,284 | $795.20 | |
| 82247 | <1% | 1,629 | $767.80 | |
| 82040 | <1% | 1,436 | $690.10 | |
| 84402 | <1% | 44 | $635.38 | |
| 84146 | <1% | 57 | $627.74 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 24 | $612.85 |
| 87807 | <1% | 99 | $546.75 | |
| 74018 | <1% | 108 | $539.22 | |
| 90696 | <1% | 30 | $535.50 | |
| 77080 | <1% | 12 | $517.86 | |
| 83605 | <1% | 1,364 | $510.16 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $479.20 |
| 82746 | <1% | 52 | $462.57 | |
| 80320 | <1% | 1,234 | $461.19 | |
| 83550 | <1% | 110 | $446.57 | |
| 83520 | <1% | 45 | $437.24 | |
| 86753 | <1% | 117 | $415.42 | |
| 90620 | <1% | 25 | $410.55 | |
| 0081A | <1% | 14 | $397.86 | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 13 | $362.62 |
| 86617 | <1% | 48 | $356.27 | |
| 85018 | <1% | 816 | $335.52 | |
| 82950 | <1% | 107 | $332.73 | |
| 86592 | <1% | 188 | $304.98 | |
| 87040 | <1% | 795 | $301.18 | |
| 73502 | <1% | 37 | $296.91 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 654 | $285.02 |
| 90716 | <1% | 13 | $273.70 | |
| 73140 | <1% | 84 | $259.06 | |
| 80326 | <1% | 286 | $245.05 | |
| 80347 | <1% | 286 | $245.05 | |
| 80364 | <1% | 286 | $235.05 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,527 | $230.50 |
| 82533 | <1% | 15 | $223.31 | |
| 84155 | <1% | 995 | $216.78 | |
| 86787 | <1% | 83 | $184.25 | |
| 84460 | <1% | 59 | $176.51 | |
| 86038 | <1% | 28 | $152.48 | |
| 73080 | <1% | 40 | $146.39 | |
| 88304 | <1% | 101 | $136.71 | |
| 99407 | <1% | 24 | $134.85 | |
| 84550 | <1% | 43 | $122.04 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,387 | $98.77 |
| 96376 | <1% | 372 | $96.18 | |
| 86580 | <1% | 16 | $86.48 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 229 | $75.90 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,709 | $74.86 |
| 82330 | <1% | 12 | $68.00 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 28 | $59.30 |
| J3490 | Unclassified drugs | <1% | 34 | $58.28 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,834 | $49.51 |
| 82248 | <1% | 18 | $40.51 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,669 | $32.25 |
| 96127 | <1% | 762 | $30.92 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 449 | $22.27 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 289 | $21.56 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,674 | $10.97 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 346 | $7.28 |
| 73090 | <1% | 12 | $6.06 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 56 | $4.84 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 300 | $2.86 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 237 | $2.64 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 20 | $0.98 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 98 | $0.91 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 165 | $0.79 |
| A9270 | Non-covered item or service | <1% | 75 | $0.45 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 165 | $0.27 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 566 | $0.17 |
| 80329 | 0% | 859 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 88 | $0.00 |
| 59430 | 0% | 26 | $0.00 | |
| 94729 | 0% | 12 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 28 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 32 | $0.00 |
| 80377 | 0% | 59 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 43 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 31 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 13 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWRIGHT, MARK (CFO)
| Provider | Location | Paid |
|---|---|---|
| Aultman Hospital | Canton, OH | $58.13M |
| Niagara Falls Memorial Medical Center | Niagara Falls, NY | $278K |
| Aultman Hospital | Canton, OH | $173K |
| Aultman Hospital | Canton, OH | $113K |
| Wayne Health Services & Supplies, INC. | Wooster, OH | $95K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.